NCT06856213
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06856213
Title Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX)
Acronym ERBIOTAX
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP

Facility Status City State Zip Country Details
Instituto Catalán de Oncología - Hospital Duran i Reynals RECRUITING Barcelona Barcelona 08908 Spain Details
Hospital Universitario Marqués de Valdecilla (Santander) RECRUITING Santander Cantabria 39008 Spain Details
Centro Oncológico de Galicia (La Coruña) RECRUITING A Coruña La Coruña 15009 Spain Details
Hospital Clínico San Carlos RECRUITING Madrid Madrid 28040 Spain Details
Hospital Universitario 12 de Octubre (Madrid) RECRUITING Madrid Madrid 28041 Spain Details
Hospital Infanta Leonor (Madrid) RECRUITING Vallecas Madrid 28031 Spain Details
Complejo Hospitalario de Navarra (Pamplona) RECRUITING Pamplona Navarre 31008 Spain Details
Complejo Hospitalario de Salamanca (Salamanca) RECRUITING Salamanca Salamanca 37007 Spain Details
Hospital Universitario de Canarias (La laguna) RECRUITING San Cristóbal de La Laguna Santa Cruz de Tenerife 38320 Spain Details
Hospital Universitario Virgen del Rocío (Sevilla) RECRUITING Seville Sevilla 41013 Spain Details
Hospital Universitario Virgen de Valme (Sevilla) RECRUITING Seville Sevilla 41014 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field